Award
NIH Reporter #1R43GM161870-01A1
Development of a Novel, Safe, Easily Standardized, and Cost-Effective Cell Growth Supplement for Diverse Cell Culture Applications
Recipient
CELL REPROGRAMMING AND THERAPEUTICS, LLC
Award Amount
$422,285.00
Ceiling
$422,285.00
Awarded
August 14, 2026
Identifier
1R43GM161870-01A1
Award to CELL REPROGRAMMING AND THERAPEUTICS, LLC for developing a novel cell growth supplement that is safe, standardized, and cost-effective, with plans for large-scale production and regulatory certification.
Description
This project aims to develop a novel cell growth supplement derived from an immortal cancer cell line to address limitations of current supplements like FBS and hPL. The Phase I study will test the mitogenic activity of the new supplement compared to existing ones, with plans for large-scale production and regulatory certification in Phase II. The goal is to create a safe, standardized, cost-effective, and scalable supplement for diverse cell culture applications.